SCHEMBL1108299

SCHEMBL1108299

C=C(Cl)C(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14971560 0.78
SCHEMBL1221578 0.75
SCHEMBL3419795 0.75
Trichloroethane SCHEMBL11841296 0.73
SCHEMBL7041977 0.70
SCHEMBL24319221 0.70 ALDH1A1 (0.32)
SCHEMBL23816617 0.68
Chloromethane SCHEMBL10458728 0.67
SCHEMBL4829929 0.67
SCHEMBL515193 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240217992-A1 RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) 2024-07-04 US disclosed
US-11874434-B2 Ophthalmic devices comprising photochromic materials with reactive substituents JOHNSON & JOHNSON VISION CARE, INC. (US) 2024-01-16 US disclosed
US-11827931-B2 Methods of preparing growing polynucleotides using nucleotides with 3′ AOM blocking group ILLUMINA CAMBRIDGE LIMITED (GB) 2023-11-28 US disclosed
CN-111233618-B Method for preparing chloroethylene compounds by using phosgene 浙江新和成股份有限公司 2022-06-07 CN disclosed
US-10689391-B2 Isoxazole analogs as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-06-23 US disclosed
CN-111233618-A Method for preparing chloroethylene compounds by using phosgene 浙江新和成股份有限公司 2020-06-05 CN disclosed
US-10450306-B2 Isoxazole analogs as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2019-10-22 US disclosed
EP-3082877-B1 CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2019-08-28 EP disclosed
US-20190194216-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2019-06-27 US disclosed
US-10197707-B2 Ophthalmic devices comprising photochromic materials with reactive sub substituents JOHNSON & JOHNSON VISION CARE, INC. (US) 2019-02-05 US disclosed
WO-2009051909-A1 COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR CELLULAR PROCESSING AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-04-23 WO disclosed
US-20090072206-A1 OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS JOHNSON & JOHNSON VISION CARE, INC. 2009-03-19 US disclosed
US-20090032782-A1 PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME TRANSITIONS OPTICAL, INC. (US) 2009-02-05 US disclosed
US-7481955-B2 Photochromic materials comprising metallocenyl groups TRANSITIONS OPTICAL, INC. (US) 2009-01-27 US disclosed
US-20080225400-A1 PHOTOCHROMIC MATERIALS AND PHOTOCHROMIC COMPOSITIONS AND ARTICLES INCLUDING THE SAME TRANSITIONS OPTICAL, INC. (US) 2008-09-18 US disclosed
US-20070278460-A1 Photochromic materials comprising metallocenyl groups TRANSITIONS OPTICAL LIMITED (IE) 2007-12-06 US disclosed
US-20070278461-A1 PHOTOCHROMIC MATERIALS COMPRISING HALOALKYL GROUPS TRANSITIONS OPTICAL, INC. (US) 2007-12-06 US disclosed
US-20070278461-A1 PHOTOCHROMIC MATERIALS COMPRISING HALOALKYL GROUPS TRANSITIONS OPTICAL, INC. (US) 2007-12-06 US disclosed
WO-2000015592-A1 SYNTHESIS AND PURIFICATION OF 3,3-DIMETHYLBUTYRALDEHYDE VIA HYDROLYSIS OF 1,1-DICHLORO-3,3-DIMETHYLBUTANE OR 1-BROMO-1-CHLORO-3,3-DIMETHYLBUTANE THE NUTRASWEET COMPANY (US) 2000-03-23 WO disclosed
US-5994593-A Synthesis and purification of 3,3-dimethylbutyraldehyde via hydrolysis of 1,1-dichloro-3,3-dimethylbutane or 1-bromo-1-chloro-3,3-dimethylbutane THE NUTRASWEET COMPANY (US) 1999-11-30 US disclosed